Sections View Full Chapter Figures Tables Videos Full Chapter Figures Tables Videos Supplementary Content ++ ABORTION ++ Population ++ Women with incomplete abortion. ++ Recommendations ++ WHO 2018 ++ Offer surgical or medical management vs. watchful waiting. If patient <13-wk gestation elects medical management, give misoprostol 600 μg orally or 400 μg sublingually. Do not use vaginal misoprostol. If patient ≥13-wk gestation elects medical management, give repeated doses of misoprostol 400 μg every 3 h sublingually, vaginally, or buccally. ++ Population ++ Women with intrauterine fetal demise between 14- and 28-wk gestation. ++ Recommendation ++ WHO 2018 ++ Offer surgical or medical management vs. watchful waiting. If patient elects medical management, give 200-mg mifepristone orally; 1–2 d later, give 400-μg misoprostol sublingually or vaginally, and repeat every 4–6 h. If mifepristone is not available or not preferred by the patient, give misoprostol 400 μg every 4–6 h as the initial treatment. ++ Population ++ Women who elect to induce an abortion. ++ Recommendations ++ WHO 2018 ++ Options include vacuum aspiration (manual or electric), dilation, and evacuation or medical management. For medical abortion, give mifepristone 200 mg once as initial dose. At least 24 h later, give misoprostol vaginally, sublingually, or buccally. If <12-wk gestation, use 800 μg. If ≥12-wk gestation give 400 μg. If mifepristone is not available, use misoprostol as initial dose. ++ Source ++ Medical Management of Abortion. Geneva: World Health Organization; 2018. License: CC BY-NC-SA 3.0 IGO. ++ CONTRACEPTION ++Table Graphic Jump LocationView Table|Favorite Table|Download (.pdf) PERCENTAGE OF WOMEN EXPERIENCING AN UNINTENDED PREGNANCY WITHIN THE FIRST YEAR OF TYPICAL USE AND THE FIRST YEAR OF PERFECT USE AND THE PERCENTAGE CONTINUING USE AT THE END OF THE FIRST YEAR: UNITED STATES % of Women Experiencing an Unintended Pregnancy Within the First Year of Use Method Typical Usea Perfect Useb Women Continuing Use at 1 Yc Male sterilization 0.15 0.10 100 Female sterilization 0.5 0.5 100 Implanon 0.05 0.05 84 Intrauterine contraceptives ParaGard (copper T) 0.8 0.6 78 Mirena (LNG-IUS) 0.2 0.2 80 Depo-Provera 3 0.3 56 NuvaRing 8 0.3 68 Evra patch 8 0.3 68 Combined pill and Progestin-only pill 8 0.3 68 Diaphragm 12 6 57 Condom Female (fc) 21 5 49 Male 15 2 53 Sponge Parous women 24 20 Nulliparous women 16 9 Withdrawal 22 4 46 Fertility awareness-based methods 24 47 Standard Days methode 5 Two-Day methode 4 Ovulation methode 3 Symptothermal methode 0.4 Spermicidesf 28 18 42 No methodg 85 85 Emergency Contraceptive Pills: Treatment with COCs initiated within 120 h after unprotected intercourse reduces the risk ... GET ACCESS TO THIS RESOURCE Sign In Username Error: Please enter User Name Password Error: Please enter Password Forgot Username? Forgot Password? Sign in via OpenAthens Sign in via Shibboleth Get Free Access Through Your Institution Contact your institution's library to ask if they subscribe to McGraw-Hill Medical Products. Access My Subscription GET ACCESS TO THIS RESOURCE Subscription Options Pay Per View Timed Access to all of AccessMedicine 24 Hour $34.95 (USD) Buy Now 48 Hour $54.95 (USD) Buy Now Best Value AccessMedicine Full Site: One-Year Individual Subscription $995 USD Buy Now View All Subscription Options